Dual role of Response gene to complement-32 in multiple sclerosis

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 17-28

  Tegla, Cosmin A ^a,b   Cudrici, Cornelia D ^a   Azimzadeh, Philippe ^a   Singh, Anil K ^a   Trippe, Richard ^a   Khan, Ali ^a   Chen, Hegang ^a   Andrian Albescu, Maria ^a   Royal, Walter ^a,c   Bever, Christopher ^a,b,c   Rus, Violeta ^a   Rus, Horea ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Veterans Administration Multiple Sclerosis Center of Excellence   (United States)

Author keywords

Apoptosis; Astrocyte; Biomarker; Gliosis; Multiple sclerosis; RGC 32

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD3 ANTIGEN; CD68 ANTIGEN; COMPLEMENT; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; FAS LIGAND; FIBRONECTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 21; MESSENGER RNA; PROCOLLAGEN; PROTEIN KINASE B; RESPONSE GENE TO COMPLEMENT 32; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ASTROCYTE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; GENE SILENCING; GLIOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RELAPSE;

ACTINS; ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; ASTROCYTES; BRAIN; CELL CYCLE PROTEINS; CELL PROLIFERATION; COLLAGEN TYPE I; COMPLEMENT SYSTEM PROTEINS; CYCLIN D1; EXTRACELLULAR MATRIX; FAS LIGAND PROTEIN; FEMALE; FIBRONECTINS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84870876101     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.09.005     Document Type: Article

References (39)

1. Aktas O., et al. Death ligands and autoimmune demyelination. The Neuroscientist 2006, 12:305-316.
2. Badea T.C., et al. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. Journal of Biological Chemistry 1998, 273:26977-26981.
3. Badea T., et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. Journal of Biological Chemistry 2002, 277:502-508.
4. Cudrici C., et al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. Journal of Immunology 2006, 176:3173-3180.
5. Cudrici C., et al. Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. Experimental and Molecular Pathology 2007, 83:198-206.
6. Cudrici C., et al. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. Journal of Neuroimmunology 2008, 203:94-103.
7. Fosbrink M., et al. Overexpression of RGC-32 in colon cancer and other tumors. Experimental and Molecular Pathology 2005, 78:116-122.
8. Fosbrink M., et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Experimental and Molecular Pathology 2009, 86:87-94.
9. Holley J.E., et al. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathology and Applied Neurobiology 2003, 29:434-444.
10. Huang W.-Y., et al. RGC-32 mediates transforming growth factor-β-induced epithelial-mesenchymal transition in human renal proximal tubular cells. Journal of Biological Chemistry 2009, 284:9426-9432.
11. Ito Y., Miyazono K. RUNX transcription factors as key targets of TGF-[beta] superfamily signaling. Current Opinion in Genetics & Development 2003, 13:43-47.
12. Jones J.L., et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). The Journal of Clinical Investigation 2009, 119:2052-2061.
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
14. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
15. Lopatinskaya L., et al. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. Journal of Neuroimmunology 2003, 138:123-131.
16. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001, 50:121-127.
17. Mohan H., et al. Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathology 2010, 20:966-975.
18. Moreels M., et al. Alpha-smooth muscle actin (alpha-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of transforming growth factor-beta 1 (TGF-beta1). Neuropathology and Applied Neurobiology 2008, 34:532-546.
19. Niculescu F., et al. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. Journal of Immunology 1997, 158:4405-4412.
20. Okuda Y., et al. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. Journal of Neuroimmunology 2006, 171:163-170.
21. Park E.S., et al. Response gene to complement 32 expression is induced by the luteinizing hormone (LH) surge and regulated by LH-induced mediators in the rodent ovary. Endocrinology 2008, 149:3025-3036.
22. Parrish-Novak J., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
23. Polman C.H., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005, 58:840-846.
24. Rus H.G., et al. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus. Journal of Immunology 1992, 148:928-933.
25. Rus H.G., et al. Sublytic complement attack induces cell cycle in oligodendrocytes. Journal of Immunology 1996, 156:4892-4900.
26. Rus H., et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11094-11099.
27. Rus H., et al. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Advances in Experimental Medicine and Biology 2006, 586:139-151.
28. Saigusa K., Imoto I., Tanikawa C., Aoyagi, Ohno K., Nakamura Y., Inazawa J. RGC32, a novel inducible p53 gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 2006, 26:1110-1121.
29. Sharief M.K. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. Journal of Neuroimmunology 2000, 109:236-243.
30. Singh A.K., et al. Transcription of human resistin gene involves an interaction of Sp1 with peroxisome proliferator-activating receptor gamma (PPARγ). PLoS One 2010, 5:e9912.
31. Sospedra M., Martin R. Immunology of multiple sclerosis. Annual Review of Immunology 2005, 23:683-747.
32. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Current Opinion in Cell Biology 2003, 15:158-163.
33. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunology 2001, 2:762-764.
34. Suvannavejh G.C., et al. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. The Journal of Clinical Investigation 2000, 105:223-231.
35. Torgler R., et al. Regulation of activation-induced Fas (CD95/Apo-1) ligand expression in T cells by the cyclin B1/Cdk1 complex. Journal of Biological Chemistry 2004, 279:37334-37342.
36. Tzartos J.S., et al. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. American Journal of Pathology 2011, 178:794-802.
37. Vlaicu S.I., et al. Epigenetic modifications induced by RGC-32 in colon cancer. Experimental and Molecular Pathology 2010, 88:67-76.
38. Wildey G.M., Howe P.H. Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells. Journal of Biological Chemistry 2009, 284:20227-20239.
39. Zipp F., et al. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. Journal of Neuroimmunology 1998, 86:151-154.